Deep Immune Profiling of Nonchimeric Tolerance of Transplants in Nonhuman Primates
非人灵长类动物移植物非嵌合耐受性的深度免疫分析
基本信息
- 批准号:10353191
- 负责人:
- 金额:$ 23.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-04-22 至 2024-03-31
- 项目状态:已结题
- 来源:
- 关键词:ApoptoticBehavior TherapyBiological MarkersBone MarrowCD4 Positive T LymphocytesCellsCellular AssayChromatinChronicClinical TrialsComputer AnalysisCytometryData SetEpigenetic ProcessFailureFoundationsFutureGenerationsGenomicsGoalsHumanImmuneImmunobiologyImmunosuppressionInfusion proceduresInvestigationKidney TransplantationLeadLeukocytesMHC Class I GenesMacacaMacaca mulattaMaintenanceMemoryMinnesotaModelingMolecularMonitorMononuclearPeripheralPersonsPhenotypePopulationPositioning AttributeProtocols documentationPublic HealthRegimenRegulatory T-LymphocyteReportingResourcesRiskRoleSamplingSorting - Cell MovementSpecificityT-LymphocyteTechniquesTestingToxic effectTranscriptTransplant RecipientsTransplantationTransplantation ToleranceTransposaseWorkbiomarker discoveryclinical translationdigitalexhaustexhaustiongraft vs host diseasehigh dimensionalityimprovedinsightisletislet allograftmultiple omicsnonhuman primatenovelpeptide Ipreventrecruitsingle cell analysisterminally differentiated effector memory (TEM) T cellstooltranscriptometranscriptome sequencingtranscriptomics
项目摘要
Abstract
Transplant (tx) tolerance would profoundly improve the lives of thousands of people who will receive tx in the
years ahead. Recently, we reported safe and consistent induction of long-term (>1 year) tolerance to islet
allografts in nonhuman primates (NHPs) with two peritx infusions of apoptotic donor leukocytes (ADLs) under
induction immunosuppression (IIS) (in part supported by U01-AI102463). While these findings are
unprecedented and suggest the possibility of nonchimeric tx tolerance in humans, further insight into the
mechanisms by which tolerance is induced and maintained will be required before clinical translation of the
protocol can be initiated. Owing to the progress made in the epigenetic, transcriptomic and cytometric profiling
of single cells and computational analyses of high-dimensional datasets, the contributions of distinct immune cell
subsets and the graft to tolerance can now be investigated with previously unimaginable explicitness.
Accordingly, the goal of the proposed studies is to harness these novel tools and existing samples to delineate
the critical factors and mechanisms responsible for tx tolerance induced by the ADLs+IIS regimen. To this end,
we have established techniques for i) tracking and sorting allospecific CD4+ T cells, ii) single-cell ATAC- & RNA-
sequencing of these sorted cells, iii) digital spatial profiling (DSP) of grafts and graft microenvironments, and iv)
mass cytometry profiling of circulating mononuclear cells with four macaque-validated CyTOF panels.
In Aim 1, we will dissect the molecular diversity of circulating allospecific CD4+ T cells from tolerant and
nontolerant tx recipients in an unbiased manner by single-cell ATAC & RNA sequencing, testing the hypothesis
that the ADLs+IIS regimen causes i) exhaustion, ii) failure to acquire a memory phenotype and iii) expansion
and activation of regulatory subsets in CD4+ T cells via epigenetic and transcriptomic alterations.
In Aim 2, we will leverage DSP to investigate the role of the graft in the maintenance of tx tolerance, testing the
hypothesis that ADLs+IIS alters intragraft transcriptomes of co-inhibitory and protective molecules that determine
immune cell recruitment to islet and kidney grafts and their survival.
In Aim 3, we will utilize high-dimensional CyTOF profiling of circulating mononuclear cells (MNCs) with existing
as well as novel multiomic-guided panels focused on exhausted/memory (Tex/mem) and regulatory (Treg and
Tr1) T cells, testing the hypothesis that the same key heterogeneous clusters among Tex, Treg and Tr1 cell
populations are associated with islet and kidney tx tolerance induced by ADLs+IIS.
The studies proposed herein will be the first to leverage the power of epigenetic, transcriptomic and cytometric
analyses of single cells for investigation of mechanisms of peripheral tx tolerance in NHPs. The datasets
generated and analyzed will present a resource for investigating the immunobiology of nonchimeric tolerance,
with implications for biomarker discovery and clinical translation of the ADLs+IIS regimen.
摘要
移植(tx)耐受性将大大改善成千上万的人谁将接受tx在世界各地的生活。
几年前最近,我们报道了安全和一致的诱导长期(>1年)的耐受性,
非人灵长类动物(NHP)中的同种异体移植物,在非人灵长类动物(NHP)中,
诱导免疫抑制(IIS)(部分由U 01-AI 102463支持)。虽然这些发现是
这是前所未有的,并表明在人类中存在非嵌合的TX耐受性的可能性,
在临床翻译之前,需要诱导和维持耐受性的机制。
可以启动协议。由于在表观遗传学、转录组学和细胞计量学分析方面取得的进展,
单细胞和高维数据集的计算分析,不同免疫细胞的贡献
现在可以用以前无法想象的明确性来研究子集和移植到耐受性。
因此,拟议研究的目标是利用这些新工具和现有样本来描绘
ADLs+IIS方案诱导耐受的关键因素和机制。为此目的,
我们已经建立了用于i)追踪和分选同种异体特异性CD 4 + T细胞,ii)单细胞ATAC- & RNA-
这些分选的细胞的测序,iii)移植物和移植物微环境的数字空间分析(DSP),和iv)
使用四个macaque验证的CyTOF板对循环单核细胞进行质谱细胞术分析。
在目标1中,我们将剖析循环同种异体特异性CD 4 + T细胞的分子多样性,
通过单细胞ATAC和RNA测序,以无偏的方式检测非耐受性tx受体,检验假设
ADL +IIS方案导致i)耗竭,ii)不能获得记忆表型,和iii)扩增
以及通过表观遗传学和转录组学改变激活CD 4 + T细胞中的调节亚群。
在目标2中,我们将利用DSP来研究移植物在维持tx耐受性中的作用,测试
假设ADL +IIS改变了共抑制和保护分子的移植物内转录组,
免疫细胞向胰岛和肾移植物的募集及其存活。
在目标3中,我们将利用循环单核细胞(MNCs)的高维CyTOF分析,
以及新的多组学指导小组,集中在耗尽/记忆(Tex/Tex)和调节(Treg和
Tr 1)T细胞,检验Tex、Treg和Tr 1细胞之间相同的关键异质簇的假设
群体与由ADL +IIS诱导的胰岛和肾tx耐受性相关。
本文提出的研究将是第一个利用表观遗传学,转录组学和细胞计数的力量。
分析单细胞以研究NHP外周毒素耐受性的机制。数据集
产生和分析将为研究非嵌合耐受性的免疫生物学提供资源,
对生物标志物的发现和ADL +IIS方案的临床转化具有意义。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Bernhard Josef Hering其他文献
Bernhard Josef Hering的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Bernhard Josef Hering', 18)}}的其他基金
Apoptotic Donor Leukocytes to Promote Kidney Transplant Tolerance
凋亡供体白细胞促进肾移植耐受
- 批准号:
10622209 - 财政年份:2023
- 资助金额:
$ 23.25万 - 项目类别:
Deep Immune Profiling of Nonchimeric Tolerance of Transplants in Nonhuman Primates
非人类灵长类动物移植物非嵌合耐受性的深度免疫分析
- 批准号:
10612925 - 财政年份:2022
- 资助金额:
$ 23.25万 - 项目类别:
Alloantigen Delivery Via ECDI-Fixed Cells For Tolerance To Monkey Islet Grafts
通过 ECDI 固定细胞递送同种异体抗原以耐受猴胰岛移植物
- 批准号:
8518234 - 财政年份:2012
- 资助金额:
$ 23.25万 - 项目类别:
Alloantigen Delivery Via ECDI-Fixed Cells For Tolerance To Monkey Islet Grafts
通过 ECDI 固定细胞递送同种异体抗原以耐受猴胰岛移植物
- 批准号:
8400970 - 财政年份:2012
- 资助金额:
$ 23.25万 - 项目类别:
Alloantigen Delivery Via ECDI-Fixed Cells For Tolerance To Monkey Islet Grafts
通过 ECDI 固定细胞输送同种异体抗原以耐受猴胰岛移植物
- 批准号:
8706034 - 财政年份:2012
- 资助金额:
$ 23.25万 - 项目类别:
EFALIZUMAB (RAPTIVA) COMBINED WITH SIROLIMUS IN TYPE 1 DIABETIC ISLET ALLOGRAFT
EFALIZUMAB (RAPTIVA) 与西罗莫司联合用于 1 型糖尿病胰岛同种移植术
- 批准号:
7951730 - 财政年份:2008
- 资助金额:
$ 23.25万 - 项目类别:
SCREENING PROCEDURE FOR ALLO-ISLET TRANSPLANTATION PROTOCOLS
同种异体胰岛移植方案的筛选程序
- 批准号:
7951667 - 财政年份:2008
- 资助金额:
$ 23.25万 - 项目类别:
CIT-03: SINGLE-CENTER, OPEN-LABEL CLINICAL TRIAL OF THE EFFICACY OF PERITRANSPLA
CIT-03:PERITRANSPLA 功效的单中心、开放标签临床试验
- 批准号:
7951709 - 财政年份:2008
- 资助金额:
$ 23.25万 - 项目类别:
CLINICAL TRIAL: HOKT3g1 (ALA-ALA), SIROLIMUS AND LOW DOSE TACROLIMUS THERAPY IN
临床试验:HOKT3g1 (ALA-ALA)、西罗莫司和低剂量他克莫司治疗
- 批准号:
7951673 - 财政年份:2008
- 资助金额:
$ 23.25万 - 项目类别:
相似海外基金
Digital cognitive-behavior therapy for anxiety and depressive disorders: Building an impactful research project from international partnerships and knowledge exchange in primary care
针对焦虑和抑郁症的数字认知行为疗法:通过初级保健领域的国际合作和知识交流建立一个有影响力的研究项目
- 批准号:
480808 - 财政年份:2023
- 资助金额:
$ 23.25万 - 项目类别:
Miscellaneous Programs
Function of cost bias and effect of cognitive behavior therapy on social anxiety in children and adolescents
成本偏差的作用及认知行为治疗对儿童青少年社交焦虑的影响
- 批准号:
23K02970 - 财政年份:2023
- 资助金额:
$ 23.25万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Combined Dialectical Behavior Therapy and Digital Cognitive Behavioral Therapy for Insomnia for Adolescents at High Risk for Suicide: A Pilot RCT
辩证行为疗法和数字认知行为疗法相结合治疗自杀高危青少年的失眠:一项试点随机对照试验
- 批准号:
10643478 - 财政年份:2023
- 资助金额:
$ 23.25万 - 项目类别:
A Randomized Clinical Trial Comparing Transdiagnostic Behavior Therapy to Disorder-Specific Psychotherapy in the Recovery of Veterans with Social Anxiety Disorder and Comorbid PTSD Symptomatology
一项随机临床试验,比较跨诊断行为疗法与特定障碍心理疗法在患有社交焦虑症和共病 PTSD 症状的退伍军人康复中的作用
- 批准号:
10746930 - 财政年份:2023
- 资助金额:
$ 23.25万 - 项目类别:
Reducing suicide risk among aging caregivers of persons with AD/ADRD: Adapting, implementing, and evaluating Dialectical Behavior Therapy skills training interventions.
降低 AD/ADRD 患者老年护理人员的自杀风险:调整、实施和评估辩证行为治疗技能培训干预措施。
- 批准号:
10730708 - 财政年份:2023
- 资助金额:
$ 23.25万 - 项目类别:
A Randomized control trial of behavior therapy of tics in Japan. Exploring the behavior model of tics.
日本抽动行为治疗的随机对照试验。
- 批准号:
22K13840 - 财政年份:2022
- 资助金额:
$ 23.25万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The Role of Behavior Therapy Combined with Buprenorphine for the Treatment of Opioid Use Disorder
行为疗法联合丁丙诺啡治疗阿片类药物使用障碍的作用
- 批准号:
10440820 - 财政年份:2022
- 资助金额:
$ 23.25万 - 项目类别:
Efficacy of digital cognitive behavior therapy for insomnia for the prevention of perinatal depression
数字认知行为疗法治疗失眠预防围产期抑郁症的疗效
- 批准号:
10429841 - 财政年份:2022
- 资助金额:
$ 23.25万 - 项目类别:
Efficacy of digital cognitive behavior therapy for insomnia for the prevention of perinatal depression
数字认知行为疗法治疗失眠预防围产期抑郁症的疗效
- 批准号:
10656415 - 财政年份:2022
- 资助金额:
$ 23.25万 - 项目类别:
Efficacy of digital cognitive behavior therapy for insomnia for the prevention of perinatal depression - supplement
数字认知行为疗法治疗失眠预防围产期抑郁症的疗效 - 补充
- 批准号:
10794868 - 财政年份:2022
- 资助金额:
$ 23.25万 - 项目类别: